｜Edited by the Content Team of Zhong Peptide BiochemicalRecently, the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) announced that the marketing application for eplontersen injection, submitted by AstraZeneca under Registration Category 5.1, has been accepted. Public information shows that this is a once-monthly antisense oligonucleotide (ASO) therapy jointly developed by AstraZeneca and Ionis Pharmaceuticals, which can be self-administered subcutaneously by patients. The drug was approved for marketing by the U.S. FDA in December 2023 to treat adults with hereditary transthyretin-mediated amyloidosis polyneuropathy (ATTRv-PN).
Eplontersen Injection is an ASO drug developed using Ionis' antisense oligonucleotide ligand conjugation (LICA) technology. This product treats hereditary and non-hereditary amyloidosis by inhibiting the production of TTR protein.Polyneuropathy.According to publicly available information from Ionis, the LICA technology platform improves the characteristics of ASO drugs in various ways by conjugating different small molecules to ASOs. This allows the drugs to be administered through multiple methods and delivered to different organs and tissues in the human body. In December 2021, AstraZeneca announced a global development and commercialization agreement with Ionis for eplontersen to jointly develop the product. December 2023AstraZeneca's Antisense Oligonucleotide Therapy, Co-developed with Ionis, Submits for Clinical Trial in China。
Since 1993, AstraZeneca has always adhered to the original intention of being "patient-centered," based on science, continuously expanding the scientific frontier, and promoting innovative practices and sustainable development in areas such as drug research and development, production operations, and business models. Over the past thirty years, AstraZeneca has been committed to becoming a localized multinational pharmaceutical company that "brings in, establishes firmly, and goes global." Relying on its global advantageous resources and deep insights into China's local pharmaceutical market, it continues to gather global wisdom and strength.
